Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Release Date: December 23, 2025

Expiration Date: December 23, 2026

Activity Overview

The neonatal Fc receptor (FcRn) rescues immunoglobulin G (IgG) from lysosomal degradation, prolonging IgG half-life. FcRn blockade accelerates degradation of pathogenic IgG autoantibodies, leading to rapid, reversible reductions in circulating AChR and MuSK antibodies without broad immune suppression. This educational program for neurologists provides a focused, clinically grounded update on the role of FcRN blockade in the management of generalized myasthenia gravis (gMG). Emphasis is placed on the pathophysiologic rationale for targeting FcRN and how this strategy translates into meaningful clinical benefit for patients.

The program features experienced neuromuscular specialists who integrate pivotal clinical trial data with real-world insights drawn from years of treating patients with gMG. Faculty review efficacy and safety outcomes from key studies of FcRN blockers, discuss patient selection and timing of therapy, and address practical considerations such as onset of action and durability of response. Participants will gain a clear understanding of where FcRN blockers fit within the evolving gMG treatment landscape and how to apply evidence-based strategies to optimize outcomes in appropriate patients.

Target Audience

This educational activity is directed toward neurologists, specialty NPs and PAs, and other HCPs involved in the management of gMG.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify the role of FcRN in the pathophysiology of generalized myasthenia gravis
• Assess emerging data for FcRN-targeted therapies for generalized myasthenia gravis in relation to treatment outcomes
• Incorporate novel agents into individualized multidisciplinary management plans for patients with generalized myasthenia gravis.